Exhibit 99.1 N-able Announces Third Quarter 2025 Results Delivers ARR Growth of 14% Year-Over-Year Exceeds Third Quarter Revenue and Adjusted EBITDA Guidance BURLINGTON, Massachusetts - November 6, 2025 - N-able, Inc. (NYSE:NABL), a global software company delivering an end- to-end cyber resilience platform, today reported results for its third quarter ended September 30, 2025. "Our strong results reflect robust demand for cybersecurity and the rising strategic relevance of N-able," said N-able president an ...

Financial Performance - Total revenues for Q3 2025 were $663.7 million, a 1.6% decrease from $674.2 million in Q3 2024[18] - Net loss for Q3 2025 was $11.4 million, or $0.04 loss per diluted share, compared to a net loss of $3.7 million, or $0.01 loss per diluted share in Q3 2024[26] - Adjusted FFO for Q3 2025 was $100.7 million, or $0.35 per diluted share, consistent with Q3 2024[28] - Core EBITDA for Q3 2025 was $148.3 million, a decrease of $9.0 million, or 5.7% from $157.2 million in Q3 2024[27] - Core FFO for Q3 2025 was $81.7 million compared to $83.9 million for Q3 2024[28] - NAREIT FFO for Q3 2025 was $43,151,000, down 22% from $55,540,000 in Q3 2024[81] - Core FFO for Q3 2025 was $81,747,000, a decrease of 2.6% from $83,897,000 in Q3 2024[81] - Adjusted FFO for Q3 2025 was $100,681,000, slightly up from $100,137,000 in Q3 2024, indicating a 0.5% increase[81] - Total revenues for Q3 2025 were $663,665,000, down 1.5% from $674,171,000 in Q3 2024[84] - Operating income for the three months ended September 30, 2025, was $16.8 million, down from $27.2 million in the prior year[76] Revenue Breakdown - Global Warehouse same store revenues decreased 1.6% on an actual basis compared to Q3 2024[18] - Global Warehouse total revenues for the three months ended September 30, 2025, were $607,014, a decrease of 0.8% compared to $612,181 in 2024[32] - Same store total revenues were $586,524, down 1.6% from $595,829 in 2024[37] - Non-same store revenues for the three months ended September 30, 2025, totaled $20,490,000, an increase from $16,352,000 in 2024[41] - Non-same store revenues totaled $56,804, with a contribution (NOI) of $5,363 for the nine months ended September 30, 2025[54] - Total revenues for the three months ended September 30, 2025, were $663,665,000, a decrease of 1.5% compared to $674,171,000 for the same period in 2024[1] Operational Metrics - Average economic occupied pallets decreased by 4.2% to 4,057 from 4,237 in 2024[32] - Economic occupancy percentage fell by 290 basis points to 73.8% compared to 76.7% in 2024[32] - Same store average economic occupied pallets declined by 4.1% to 3,969 from 4,137 in 2024[37] - Same store economic occupancy percentage dropped by 280 basis points to 75.5% compared to 78.3% in 2024[37] - The average economic occupancy percentage for the warehouse segment decreased to 74.1% from 78.1% in the prior year, representing a decline of 400 basis points[46] - The average physical occupied pallets decreased to 3,467 for the nine months ended September 30, 2025, down 7.4% from 3,744 in 2024[46] Cost and Expenses - Total selling, general and administrative expenses guidance for 2025 is $270 million to $280 million, including $23 million to $25 million for share-based compensation[20] - The total same store cost of operations for Q3 2025 was $391.3 million, up from $373.9 million in Q2 2025, reflecting a 4.0% increase[124] - Selling, general, and administrative expenses increased to $(70,982,000) for the three months ended September 30, 2025, compared to $(63,663,000) in 2024, an increase of 11.5%[1] - Repair and maintenance expenses totaled $30.8 million for the three months ended September 30, 2025, compared to $33.0 million for the same period in 2024[111] Debt and Liquidity - As of September 30, 2025, the company had total liquidity of approximately $798.9 million, including cash and available capacity on its revolving credit facility[64] - Total net debt outstanding was approximately $4.1 billion, with a net debt to pro forma Core EBITDA ratio of approximately 6.7x[64] - Total debt outstanding as of September 30, 2025, was $4,127,571,000, with a weighted average effective interest rate of 4.15%[86] - The Company’s total debt as a percentage of total assets was 33%, well below the 60% limit set by debt covenants[97] - The Company’s interest coverage ratio was 3.6x, exceeding the required minimum of 1.5x as of September 30, 2025[97] Strategic Initiatives - The company aims to enhance efficiency and reduce costs through its transportation services, including consolidation and freight management[2] - The third-party managed segment is expected to drive growth by providing integrated services to food manufacturers and retailers, enhancing operational efficiency[3] - The company has four sites in the development and expansion phase that will be added to the non-same store pool when operations commence[42] - The Company completed the Houston acquisition on March 17, 2025, for total cash consideration of $108.4 million, enhancing its market position[113] - The company has 5 projects in process, with a total estimated cost of $243 million and an expected stabilized NOI of $50 million[121] Dividend and Shareholder Returns - The Company's Board of Directors declared a 5% increase in the dividend to $0.23 per share for Q3 2025, paid on October 15, 2025[66] Miscellaneous - The Company utilizes various non-GAAP financial measures, including NAREIT FFO and Core EBITDA, to supplement its performance analysis[68] - All quarterly amounts and non-GAAP disclosures within this filing shall be deemed unaudited[148] - The document indicates a total of 33 references to key financial data[149]

Revenue Growth - Third quarter 2025 total revenues and other income were $115.5 million, a 123% increase from $51.8 million in Q3 2024, driven by higher royalty revenue and gains from business transactions [3]. - Royalty revenue for Q3 2025 was $46.6 million, up 47% from $31.7 million in Q3 2024, primarily due to royalties from Travere Therapeutics' Filspari, Merck/Verona Pharma's Ohtuvayre, and Recordati's Qarziba [3]. - Year-to-date total revenues for the nine months ended September 30, 2025, were $208.4 million, a 68% increase from $124.3 million in the same period in 2024 [6]. - Ligand reported total revenues and other income of $115,461,000 for the three months ended September 30, 2025, compared to $51,812,000 for the same period in 2024, representing a 123% increase [38]. - Core revenues and other income reached $86,892,000 for the three months ended September 30, 2025, compared to $51,812,000 in the prior year, reflecting a 67.6% increase [42]. Earnings and Guidance - Ligand raised its 2025 full year revenue guidance to $225 million - $235 million, up from the previous guidance of $200 million - $225 million [1]. - Adjusted earnings per diluted share guidance for 2025 increased to $7.40 - $7.65, compared to the previous range of $6.70 - $7.00 [1]. - GAAP net income for Q3 2025 was $117.3 million, or $5.68 per diluted share, compared to a net loss of $7.2 million, or $0.39 per share, in Q3 2024 [5]. - Net income for the three months ended September 30, 2025, was $117,273,000, compared to a net loss of $7,172,000 in the same quarter of 2024, indicating a significant turnaround [42]. - Diluted net income per share for the three months ended September 30, 2025, was $5.68, a significant improvement from a loss of $0.39 per share in the same quarter of 2024 [42]. Research and Development - Research and development expenses for Q3 2025 were $21.0 million, significantly up from $5.7 million in Q3 2024, due to one-time charges related to royalty financing agreements [3]. - Ligand's research and development expenses for the nine months ended September 30, 2025, were $77,671,000, significantly higher than $17,000,000 for the same period in 2024 [38]. - The company incurred $18,659,000 in R&D funding expenses for the three months ended September 30, 2025, compared to $725,000 in the same period of 2024 [42]. Acquisitions and Investments - Ligand completed a $460 million convertible senior notes offering due 2030, with net proceeds of approximately $445 million after fees and expenses [11][12]. - Ligand invested $25 million in Orchestra BioMed's late-stage cardiology programs, with an additional $15 million contingent on certain conditions [14]. - Ligand purchased global royalty rights to AT220 and related fees for $7 million, with an additional $4 million contingent on commercial milestones [13]. - The company completed the acquisition of Verona Pharma, adding Ohtuvayre, a treatment for chronic obstructive pulmonary disease, to its portfolio [24]. Financial Position - Total assets increased to $1,476,772,000 as of September 30, 2025, up from $941,774,000 on December 31, 2024, representing a growth of 57% [40]. - Total current assets rose to $753,920,000 as of September 30, 2025, compared to $331,559,000 at the end of 2024, marking a 126.5% increase [40]. - Total liabilities increased to $526,601,000 as of September 30, 2025, compared to $111,335,000 at the end of 2024, representing a 373.5% rise [40]. - The long-term portion of financial royalty assets increased to $206,332,000 as of September 30, 2025, up from $185,024,000 at the end of 2024, showing a growth of 11.5% [40]. Other Income - Ligand's income from the Pelthos transaction, specifically the Zelsuvmi out-license, was $24,503,000 for the three months ended September 30, 2025 [38]. - The company reported a total of $53.1 million in income related to the divestiture of its Pelthos subsidiary, which included $24.5 million from the out-license of Zelsuvmi and a $28.6 million gain on the sale of the business [46].

Production and Operational Performance - Q3 2025 run-rate daily production reached 25,530 Boe/d, exceeding the midpoint of guidance[4] - The company maintained an active rig count of 86, representing approximately 16% market share of U.S. land rigs[4] - Kimbell's production increased organically by approximately 1% from Q2 to Q3 2025, demonstrating resilience amid industry headwinds[5] - Kimbell's major properties had 7.07 net DUCs and net permitted locations, exceeding the estimated 6.5 net wells needed to maintain flat production[4] - Cash G&A per BOE was $2.51 in Q3 2025, below the midpoint of guidance, indicating operational discipline[4] - Kimbell Royalty Partners, LP's cash G&A per Boe is a key metric for evaluating operational performance within the energy sector[30] Financial Performance - Q3 2025 total revenues amounted to $80.6 million, with net income of approximately $22.3 million[10] - Total revenues for Q3 2025 were $80,620,000, a decrease of 3% from $83,785,000 in Q3 2024[27] - Oil, natural gas, and NGL revenues increased to $76,807,000 in Q3 2025, up from $71,069,000 in Q3 2024, representing a growth of 8%[27] - Net income for Q3 2025 was $22,323,000, compared to $25,805,000 in Q3 2024, reflecting a decline of 13%[27] - Adjusted EBITDA attributable to Kimbell Royalty Partners, LP for Q3 2025 was $53,903,000, slightly up from $53,522,000 in Q3 2024[32] - Consolidated EBITDA for Q3 2024 was $66,359,000, compared to $59,891,000 for Q3 2025, indicating a decrease of about 9.7%[36][38] Cash Distribution and Debt Management - Kimbell announced a cash distribution of $0.35 per common unit for Q3 2025, reflecting a payout ratio of 75% of cash available for distribution[4] - The cash distribution declared for Q3 2025 was $0.35 per common unit, while cash available for distribution per common unit was $0.47[34] - The company plans to utilize 25% of cash available for distribution to repay approximately $12.6 million of outstanding borrowings[8] - Long-term debt as of September 30, 2025, stood at $448,496,000[25] - Net debt to trailing twelve month consolidated Adjusted EBITDA was approximately 1.6x as of September 30, 2025[13] - The company allocated 25% of cash available for distribution to pay outstanding borrowings under its secured revolving credit facility[36] Year-over-Year Comparisons - Net income for the three months ended September 30, 2024, was $25,805,000, while for the same period in 2025, it decreased to $22,323,000, reflecting a year-over-year decline of approximately 9.6%[36][38] - Cash available for distribution on common units was $43,469,000 for Q3 2025, compared to $44,228,000 in Q3 2024[32] - Cash available for distribution on common units for Q3 2024 was $44,228,000, resulting in a cash distribution per common unit of $0.55, while the declared distribution was $0.41[36] Expenses and Losses - The cash interest expense for Q3 2024 was $5,123,000, which increased to $9,782,000 in Q3 2025, reflecting a significant rise of approximately 91.5%[36][38] - The company reported a depreciation and depletion expense of $32,155,000 for Q3 2024, slightly decreasing to $31,043,000 in Q3 2025[36][38] - The gain on derivative instruments for Q3 2024 was a loss of $7,066,000, while for Q3 2025, it was a loss of $1,793,000, indicating a reduction in losses year-over-year[36][38] Shareholder Metrics - The weighted average number of common units outstanding increased to 91,170,092 in Q3 2025 from 78,977,450 in Q3 2024[27] - The cash distribution to Series A preferred unitholders for Q3 2024 was $4,156,000, while the distribution to Class B unitholders was minimal at $15,000[36]

November 6, 2025 Third quarter revenue grew 28% year-over-year to $886 million Robust growth of larger customers, with about 4,060 $100k+ ARR customers, up from about 3,490 a year ago Reached a milestone of over 1,000 integrations on the Datadog unified platform NEW YORK-- Datadog, Inc. (NASDAQ:DDOG), the monitoring and security platform for cloud applications, today announced financial results for its third quarter ended September 30, 2025. "Datadog had a strong third quarter, with 28% year-over-year reven ...

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights Completed Equity Of ering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 µg) and Dif erentiated Safety and Tolerability Profile Entered Into Clin ...

Revenue and Sales Performance - Total revenue for the three months ended September 30, 2025, was $384.238 million, compared to $327.252 million for the same period in 2024, representing a year-over-year increase of approximately 17.4%[35] - Aftermarket part sales for the three months ended September 30, 2025, were $24.9 million, up from $21.1 million in 2024, reflecting a growth of about 17.9%[35] - The company recognized revenue of $11.8 million for the nine months ended September 30, 2025, that was included in the contract liability balance at the beginning of the period, compared to $12.4 million for the same period in 2024[45] - For the three months ended September 30, 2025, AAON Oklahoma reported external sales of $238.7 million, while AAON Coil Products and BASX reported external sales of $70.2 million and $75.2 million, respectively[142] Financial Position and Assets - Contract assets increased to $207.739 million as of September 30, 2025, from $135.820 million at the end of 2024, indicating a significant rise of approximately 53%[44] - Total accounts receivable increased to $267,568 thousand as of September 30, 2025, up from $148,472 thousand in December 31, 2024, representing an increase of 80.3%[53] - Total inventories increased to $256,728 thousand as of September 30, 2025, compared to $192,612 thousand as of December 31, 2024, reflecting a growth of 33.3%[54] - Total property, plant, and equipment rose to $947,478 thousand as of September 30, 2025, from $819,998 thousand as of December 31, 2024, marking an increase of 15.6%[56] - Total long-lived assets increased to $608.7 million as of September 30, 2025, compared to $525.8 million as of December 31, 2024[144] Liabilities and Debt - The company’s total contract liabilities as of September 30, 2025, were $(19.974) million, compared to $(14.913) million at the end of 2024, indicating an increase in liabilities[44] - The total minimum lease obligations, net of present value of minimum lease payments, amounted to $14,902 thousand as of September 30, 2025[52] - The company entered into a Third Amendment to its Loan Agreement, including an $80 million term loan and a $200 million revolving credit facility, which was increased to $230 million in April 2025[66] - As of September 30, 2025, the total Revolver commitment was $500 million, with outstanding borrowings of $360,142,000, leaving $139,204,000 available[68] - The Company had an outstanding balance of $360.1 million on its combined Revolver and Term Loan as of September 30, 2025[208] Expenses and Costs - Costs incurred on uncompleted contracts for the nine months ended September 30, 2025, totaled $192.207 million, compared to $132.844 million for the same period in 2024, marking an increase of approximately 44.7%[45] - Depreciation expense for the three months ended September 30, 2025, was $18,419 thousand, compared to $14,636 thousand for the same period in 2024, representing a 25.5% increase[57] - The total amount paid to representatives for the three months ended September 30, 2025, was $11.1 million, compared to $10.7 million for the same period in 2024, reflecting a year-over-year increase of approximately 3.7%[43] - Accrued liabilities increased to $120,468,000 as of September 30, 2025, from $99,347,000 as of December 31, 2024, representing a growth of approximately 21.3%[65] Tax and Compliance - The effective income tax rate for the nine months ended September 30, 2025, was 16.4%, compared to 19.3% for the same period in 2024[75] - The company recorded deferred tax assets of $10.2 million (Federal) and $2.3 million (State) related to net operating loss carryforwards of approximately $48.6 million as of September 30, 2025[84] - The company recognized an increase in deferred tax liabilities of $30.9 million due to changes in tax law effective January 1, 2025[82] Shareholder and Employee Compensation - The company awarded annual merit raises resulting in a 3.3% increase in wages in March 2024 and a 4.0% increase in March 2025[29] - The total share-based compensation expense for the nine months ended September 30, 2025, was $13.4 million, compared to $12.8 million for the same period in 2024[98] - The Company matches 175.0% up to 6.0% of employee contributions in its defined contribution plan[102] - Contributions to the defined contribution plan increased to $5,975,000 for the three months ended September 30, 2025, compared to $4,570,000 for the same period in 2024, representing a 30.8% increase[103] Market and Operational Challenges - The company is facing inflationary cost pressures and supply chain disruptions due to global health issues, impacting demand for products and financial position[209] - There are concerns regarding the tightening of labor markets, affecting the ability to hire employees for continued growth[209] - The company is monitoring fluctuations in the commercial/industrial new construction market, which may influence future performance[209] - Future levels of capital expenditures and research and development are critical for the company's growth strategy[209] - The company is focused on the integration of acquired businesses to realize synergies and cost savings[209] - Legal, regulatory, and environmental compliance is essential for the company's operations and product standards[209] - The company is assessing the creditworthiness of customers and their access to capital, which could affect revenue generation[209] - Changes in interest rates and competitive factors are being closely monitored as they may impact financial results[209] - The company is addressing cybersecurity risks and potential impacts on information technology systems[209] - The timing and market acceptance of new product introductions are crucial for future revenue growth[209] Profitability and Shareholder Returns - Basic earnings per share for the nine months ended September 30, 2025, was $0.93, down from $1.77 in 2024, a decline of 47.2%[109] - The company repurchased approximately $30.0 million of shares as of September 30, 2025, with $70.0 million remaining under the current board authorization[110] - The company declared cash dividends of $0.10 per share for the periods ending March 5, 2025, May 13, 2025, and August 14, 2025, with an annualized dividend of $0.40[113] - The company reported net income of $30,782,000 for the three months ended September 30, 2025, compared to $52,625,000 in 2024, a decrease of 41.5%[109]

Financial Performance - Net product revenue for Q3 2025 was $115.4 million, a 13% increase year-over-year, driven by higher sales of NUZYRA and XACDURO[85]. - Total revenues for the three months ended September 30, 2025, increased by $13.8 million (14%) to $116.1 million compared to $102.3 million in the same period of 2024[100]. - Product revenue, net, rose by $13.5 million (13%) to $115.4 million for the three months ended September 30, 2025, driven by increased sales of NUZYRA and VYVGART[101]. - Collaboration revenue surged by $0.3 million (76%) to $734,000 for the three months ended September 30, 2025, reflecting promotional activities in mainland China[105]. - Net loss for the three months ended September 30, 2025, was $36.0 million, a reduction of $5.7 million (14%) compared to a net loss of $41.7 million in the same period of 2024[120]. - Net product revenue for the nine months ended September 30, 2025, increased by $41.0 million (14%) to $330.1 million compared to $289.1 million in the same period of 2024[100]. - Interest income decreased by $0.7 million (8%) to $8.3 million for the three months ended September 30, 2025, primarily due to lower interest rates[115]. - Foreign currency gains were $6.4 million for the three months ended September 30, 2025, down from $14.5 million in the same period of 2024, driven by RMB appreciation against the U.S. dollar[117]. - The company reported a loss per ordinary share of $0.03 for the three months ended September 30, 2025, compared to a loss per ordinary share of $0.04 in the same period of 2024[120]. Research and Development - The company expects to continue incurring substantial costs related to research and development and commercialization activities[83]. - The global Phase I clinical trial of Zocilurtatug Pelitecan (Zoci) showed a 68% overall response rate in 2L patients with ES-SCLC[86]. - The FDA granted Breakthrough Therapy Designation to Povetacicept for IgA nephropathy, with full enrollment of the Phase III study completed[91]. - The NMPA granted Innovative Medical Device Designation for TTFields therapy for pancreatic cancer, with plans to file for regulatory approval in Q4 2025[90]. - As of September 30, 2025, the company may be required to pay up to $211.0 million in development and regulatory milestone payments for current clinical programs[98]. Expenses and Cash Flow - Research and development expenses decreased by $18.1 million (27%) to $47.9 million for the three months ended September 30, 2025, primarily due to reduced licensing fees and personnel costs[106]. - Selling, general, and administrative expenses increased by $2.9 million (4%) to $70.1 million for the three months ended September 30, 2025, mainly due to higher selling expenses for NUZYRA and VYVGART[114]. - Net cash used in operating activities decreased by $34.3 million to $124.8 million for the nine months ended September 30, 2025, compared to $159.1 million in 2024[140]. - Net cash provided by investing activities increased by $346.6 million, primarily due to a $313.7 million increase in proceeds from the maturity of short-term investments[141]. - As of September 30, 2025, the company had cash and cash equivalents of $717.2 million, restricted cash of $101.1 million, and short-term investments of nil[152]. - The net increase in cash, cash equivalents, and restricted cash was $267.5 million for the nine months ended September 30, 2025[139]. Debt and Financial Commitments - The company had short-term debt of $203.0 million as of September 30, 2025, compared to $131.7 million as of December 31, 2024[156]. - The two largest customers accounted for approximately 19% of total accounts receivable as of September 30, 2025[153]. - The company had commitments of $0.7 million related to commercial manufacturing development activities and capital expenditures as of September 30, 2025[136]. - The company has identified opportunities to access capital through debt arrangements totaling approximately $275.4 million to support working capital needs in mainland China[137]. - A 100-basis point increase in interest rates would not materially increase the company's interest expense on short-term debt[156]. Leadership and Strategy - The company appointed Dr. Shan He as Senior Vice President, Chief Business Officer, to lead strategy for business development and partnerships[92]. - The company plans to increase patient access to existing commercial products through NRDL listing and supplemental insurance coverage[93]. - The company anticipates fluctuations in financial results based on the success of commercial products and research and development expenses[84].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q ____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40969 _______________ ...

Exhibit 99.1 CareCloud Reports Third Quarter 2025 Results Raises Revenue Guidance, Completes Medsphere Acquisition and Accelerates AI Initiative SOMERSET, N.J. November 06, 2025 (GLOBE NEWSWIRE) - CareCloud, Inc. (Nasdaq: CCLD, CCLDO), a leader in healthcare technology and generative AI solutions, today announced strong financial results for the quarter ended September 30, 2025, and is increasing its full-year 2025 revenue guidance to $117 – $119 million, up from the initial range of $111 – $114 million. Ca ...